GlassScriptPhysician profile
Robin Lynn Ferguson
NPI 1376507681
$7,300.15
in general payments reported to CMS, 2019-2025
19 companies · $538 in 2025
The $538 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $892 · 2020: $253 · 2021: $666 · 2022: $1,249 · 2023: $2,647 · 2024: $1,055 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,961 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,250 · Education: $29.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,960.63 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,250.00 |
| Education | $29.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,470.04 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $1,665.41 | 2019-2025 | |
| Gilead Sciences, INC. | $922.83 | 2019-2025 | Epclusa |
| E.R. Squibb & Sons, L.L.C. | $681.03 | 2021-2023 | Zeposia |
| Madrigal Pharmaceuticals | $332.13 | 2024-2025 | Rezdiffra |
| Janssen Biotech, INC. | $235.32 | 2019-2024 | Stelara, Tremfya |
| Johnson & Johnson Health Care Systems INC. | $191.61 | 2021-2023 | Stelara |
| Phathom Pharmaceuticals, INC. | $187.00 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $158.04 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $132.20 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.20 | 2024-2025 | Eohilia |
| Celgene Corporation | $66.08 | 2022-2023 | Zeposia |
| Medtronic, INC. | $51.41 | 2024 | Nexpowder |
| Ferring Pharmaceuticals INC. | $41.09 | 2019-2020 | |
| Redhill Biopharma INC. | $36.85 | 2022-2023 | Talicia, Movantik, Aemcolo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $18.13 | 2022 | |
| Merck Sharp & Dohme LLC | $16.06 | 2020 | |
| Allergan, INC. | $14.20 | 2019 | |
| Olympus America INC. | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Ferguson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.